Deal Library / Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. — Pharma Deals

The Pharma Closeout tracks 25 deals, $141.7B in disclosed deal value, 14 with a post-close Outcome Score for Takeda Pharmaceutical Company Ltd..

Median Critic Score: 75  ·  Median Outcome Score: 54

Best outcome: Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi (82)  ·  Weakest outcome: Takeda Pharmaceutical Company Ltd. / Shire plc (8)

All 25 deals

• Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi — 2022 · $6.0B · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals — 2003 · $8.8B · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals — 2003 · $5.2B · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Nycomed — 2011 · $13.7B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals — 2008 · $8.8B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. — 2018 · $1.2B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. — 2026 · $600M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / Tesaro Inc. — 2017 · $340M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals — 2017 · $5.2B · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / URL Pharma, Inc. — 2012 · $800M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / Intellikine, Inc. — 2011 · $310M · Underwhelmed — fell short of the thesis.
• Takeda Pharmaceutical Company Ltd. / Wave Life Sciences Ltd. — 2018 · $2.0B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / TiGenix NV — 2018 · $640M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Shire plc — 2018 · $62.0B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Iambic Therapeutics, Inc. — 2026 · $1.7B
• Takeda Pharmaceutical Company Ltd. / Innovent Biologics, Inc. — 2025 · $11.4B
• Takeda Pharmaceutical Company Ltd. / Novavax Inc. — 2025
• Takeda Pharmaceutical Company Ltd. / Nabla Bio, Inc. — 2025 · $1.0B
• Takeda Pharmaceutical Company Ltd. / BridGene Biosciences, Inc. — 2025 · $770M
• Takeda Pharmaceutical Company Ltd. / Degron Therapeutics Ltd. — 2024 · $1.2B
• Takeda Pharmaceutical Company Ltd. / AC Immune SA — 2024 · $2.2B
• Takeda Pharmaceutical Company Ltd. / HUTCHMED (China) Limited — 2023 · $1.1B
• Takeda Pharmaceutical Company Ltd. / Nimbus Therapeutics (Lakshmi subsidiary, TYK2 program) — 2022 · $6.0B
• Takeda Pharmaceutical Company Ltd. / Novavax Inc. — 2021 · $350M
• Takeda Pharmaceutical Company Ltd. / GammaDelta Therapeutics Limited — 2021 · $350M

← Deal Library  ·  Interactive search  ·  How we score deals